By Alexander Stone
The syringe barely touches skin before the craving vanishes. A packet of McVitie’s, once an automatic afternoon reflex, now sits on the counter like a stranger’s post. The biscuit is still there. The desire is not. This is not willpower. This is pharmacology – and it is rewriting the grammar of British eating at a pace that has caught food manufacturers, retailers, and regulators off guard.
GLP-1 receptor agonists, the class of drugs that includes semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), were developed to manage type 2 diabetes and obesity. But their most disruptive consequence may not be clinical at all. It is commercial, cultural, and – according to a growing body of peer-reviewed research – neurological. These drugs do not merely suppress appetite. They reshape what people want.
The Neurochemistry of Changed Desires
A landmark study published in Food Quality and Preference by researchers at the University of Arkansas surveyed 1,955 respondents – current GLP-1 users, former users, and controls – and found that 71 per cent reported drastic reductions in ultra-processed food consumption. Consumption of fizzy drinks, refined grains, and red meat fell among roughly half of users. Alcohol intake dropped sharply. Yet only three categories showed increased consumption: fruits, leafy greens, and water.
“Our study shows that adoption of GLP-1 agonists changes both the amount and types of food people eat,” said Jayson Lusk, professor and dean of Oklahoma State University’s Division of Agricultural Sciences and Natural Resources and a co-author of the study. “Food companies will be challenged as demand for processed foods falls but will have opportunities as demand for fruits and vegetables increases.”
The mechanism is not purely appetite suppression. GLP-1 agonists mimic the natural gut hormone glucagon-like peptide-1, which is released after eating and slows gastric emptying, signalling satiety to the brain. But they also modulate the nucleus accumbens – the brain’s reward centre – dampening the dopamine response to hyperpalatable foods while leaving the subtler pleasures of whole foods relatively intact. A December 2025 study in the Journal of Marketing Research, drawing on transaction data from tens of thousands of US households via Numerator, confirmed that this neurochemical shift translates into measurable behavioural change: households reduced grocery spending by 5.3 per cent within six months of a member starting a GLP-1 drug. Among higher-income households, the figure rose to 8.2 per cent. Spending at fast-food restaurants and coffee shops fell by roughly 8 per cent.
The researchers, Sylvia Hristakeva and Jura Liaukonyte at Cornell University, also found that when users discontinued the medication, their spending reverted to pre-adoption levels – and their grocery baskets became slightly less healthy than before they started, driven partly by increased spending on confectionery.
Britain’s Grocery Shelves Respond
In the United Kingdom, where approximately 5 per cent of adults now use GLP-1 medications according to a March 2026 analysis by law firm Charles Russell Speechlys, the retail response has been swift and visible. Sainsbury’s, Tesco, Marks & Spencer, Co-op, and Morrisons all launched dedicated GLP-1-aligned product ranges in early 2026. These are not mere marketing exercises. The ranges feature portion-controlled meals with elevated protein and fibre, reduced calorie density, and added micronutrients designed to supplement the reduced dietary intake that GLP-1 use entails.
Smaller portions have become a premium proposition. Nutrient density, rather than pack size, now justifies higher price points. Greggs, the bakery chain with more than 2,600 outlets across Britain, reported in January 2026 that appetite-suppressing drugs were having “no doubt” an impact on its profits. Chief executive Roisin Currie told the BBC that customers on GLP-1 drugs were actively seeking “protein and fibre” and smaller portions. The chain responded by introducing products such as peeled boiled eggs and protein-focused ranges – a far cry from its traditional best-selling pasties and sausage rolls.
A January 2026 analysis by Research and Markets projected global GLP-1 drug sales would rise from $76 billion in 2025 to $162 billion by 2031. The report identified UK retailers as moving faster than brand manufacturers in GLP-1-aligned innovation, setting a template that multinational food companies are scrambling to follow.
Beyond Appetite: The Addiction Connection
Perhaps the most unexpected dimension of GLP-1’s reach is its apparent effect on addictive behaviours beyond eating. A randomised clinical trial published in 2025 found that low-dose semaglutide significantly reduced alcohol cravings and consumption in adults with alcohol use disorder, with medium to large effect sizes for grams of alcohol consumed. The same trial noted a significant reduction in cigarette consumption among participants who smoked.
These findings are consistent with the hypothesis that GLP-1 agonists dampen dopamine-driven reward loops more broadly. “We’re witnessing a pharmacological rebalancing of pleasure economics,” neuroscientist Dr Raj Patel observed in the original Creativitys.UK analysis of this phenomenon. “What’s vanishing isn’t joy, but the tyranny of craving.”
A June 2026 study published in Nature Communications by researchers at the University of California San Diego went further, presenting the first randomised, placebo-controlled clinical evidence that semaglutide slows biological ageing. Using epigenetic clocks – which measure DNA methylation patterns to assess cellular ageing – the team found that semaglutide slowed the pace of biological ageing by 9 per cent across markers linked to inflammation, brain, heart, kidney, liver, and metabolic health. The implications extend far beyond weight management into the territory of longevity science.
The Regulatory Tightrope
The speed of commercial adaptation has outpaced regulatory clarity. In the United Kingdom, the Advertising Standards Authority, the Medicines and Healthcare products Regulatory Agency, and the General Pharmaceutical Council jointly issued an updated enforcement notice in 2025, outlining compliance guidance for businesses advertising GLP-1-adjacent products. The MHRA has powers to monitor and investigate complaints relating to medicines advertising and has continued to take enforcement action.
The challenge is twofold. Food businesses launching GLP-1-friendly ranges must navigate strict nutrition claims rules without implying therapeutic benefit. Online prescribing models face layered healthcare registration requirements across the UK’s regulatory bodies. The Osborne Clarke law firm noted in March 2026 that advertising GLP-1 products carries “real legal risk” and that regulators are actively using AI tools to detect breaches – a striking example of technology being deployed to police the commercialisation of technology.
At the population level, the policy questions are profound. If GLP-1 adoption lowers obesity rates but simultaneously spikes demand for fresh produce, does subsidising broccoli become a public health imperative? The UK government’s recent ban on junk food advertising before 9pm represents one approach; the integration of GLP-1 prescribing with dietary support programmes represents another. What remains unclear is whether the food system – from field to fork – can adapt quickly enough to absorb a structural shift in demand that shows no sign of reversing.
The Emotional Residue of Craving
Even as GLP-1 drugs rewrite neural pathways, emotional attachments to food persist. A January 2026 study published in the Journal of Medical Internet Research, which analysed 60 online medication reviews, found that two-thirds of respondents reported reduced appetite, food cravings, or body weight. Gastrointestinal side effects were common – reported by 62 per cent of reviewers – but did not significantly influence satisfaction ratings or decisions to continue treatment. What did influence discontinuation was the perception that the drug was no longer working, particularly as weight loss plateaued after approximately one year.
There is a nostalgia dimension too. Even users who have largely abandoned ultra-processed foods report occasional purchases of chocolate or crisps “for memory’s sake” – a behaviour that has spawned a niche market in luxury heritage confectionery brands targeting reformed palates with single-origin, small-batch products priced at a premium.
A Post-Hyperpalatable Future
The trajectory is clear, even if the destination remains uncertain. GLP-1 drugs have achieved what decades of nutritional education, sugar taxes, and public health campaigns largely failed to accomplish: they have made whole foods aspirational and ultra-processed foods genuinely unappealing to a significant and growing segment of the population. Whether this constitutes liberation or dependence – empowerment or the outsourcing of willpower to pharmaceutical intervention – is a question that sits at the intersection of medicine, ethics, and culture.
What is not in question is the scale of the disruption. The arc of British food culture, from the post-war rationing mentality to the ultra-processed abundance of the twenty-first century, is being bent again – this time by a molecule that mimics a hormone most people have never heard of, delivered via a pen-injector that fits in a coat pocket. The high street has noticed. The question is whether the rest of the system will keep pace.
